Skip to main content

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.

Eli Lilly (LLY) - Get Free Report reported higher earnings and sales for the latest quarter and reaffirmed its financial guidance for 2017. For the fourth quarter, Lilly reported an adjusted profit of 95 cents a share, up 22%. Lilly's revenue increased 7% and was better than analysts' forecasts. For 2017, Lilly is forecasting adjusted earnings in the range of $4.05 to $4.15 a share, with revenue ranging between $21.8 billoin and $22.3 billion. Lilly's CEO David Ricks was among the pharmaceutical industry executives meeting with President Trump Tuesday morning, where Trump said he wanted to see lower drug prices.